Q32 Bio (Q32 Bio) Days Payable : 0.00 (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Q32 Bio Days Payable?

Q32 Bio's average Accounts Payable for the three months ended in Mar. 2024 was $4.21 Mil. Q32 Bio's Cost of Goods Sold for the three months ended in Mar. 2024 was $0.00 Mil.

The historical rank and industry rank for Q32 Bio's Days Payable or its related term are showing as below:

QTTB's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 148.145
* Ranked among companies with meaningful Days Payable only.

Q32 Bio's Days Payable stayed the same from Dec. 2022 (0.00) to Mar. 2024 (0.00). stayed the same

Q32 Bio Days Payable Historical Data

The historical data trend for Q32 Bio's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Q32 Bio Days Payable Chart

Q32 Bio Annual Data

Trend

Dec21

Dec22

Dec23

Days Payable

Q32 Bio Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Days Payable	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Q32 Bio's Days Payable

For the Biotechnology subindustry, Q32 Bio's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Q32 Bio's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Q32 Bio's Days Payable distribution charts can be found below:

* The bar in red indicates where Q32 Bio's Days Payable falls into.

Q32 Bio Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Q32 Bio's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (1.435	+	3.468)	/	2 )	/	0	*	365
=	2.4515					/	0	*	365
=	N/A

Q32 Bio's Days Payable for the quarter that ended in Mar. 2024 is calculated as:

	Days Payable (Q: Mar. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2023 )	+	Accounts Payable (Q: Mar. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
=	( (3.468	+	4.96)	/	2 )	/	0	*	365 / 4
=	4.214					/	0	*	365 / 4
=	N/A

Q32 Bio Days Payable Related Terms

Thank you for viewing the detailed overview of Q32 Bio's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Q32 Bio (Q32 Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q32 Bio Inc (NAS:QTTB) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

830 Winter Street, Waltham, MA, USA, 02451

Website

https://www.q32bio.com

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

Q32 Bio (Q32 Bio) Headlines

From GuruFocus

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer

By PRNewswire • 04-03-2024